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Abstract 
 
Antimicrobial peptides (AMPs) are a sufficient and diverse group of molecules that are 
derive from various invertebrate, plant and animal species. AMPs possess a variety of 
biological activity, such as anticancer, antivirus and so on. Nowadays, a growing number 
of AMPs are considered as promising candidate of new drug. 
This thesis focused on the antimicrobial peptide (QUB-1439) which was isolated from 
the skin secretion of Hylarna guentheri. It is the first time to identify the biosynthetic 
precursor encoding cDNA of QUB-1439 from the skin secretion-derived cDNA library 
though the mature peptide sequence, FLPLLFGAISHLL-NH2, has been identified before. 
Subsequently, QUB-1439 was synthesised by Tribute peptide synthesiser. Then, 
MALDI-TOF was used to check the molecular weight of the synthetic peptide. The crude 
peptide was purified by RP-HPLC. Finally, a series assays were performed to test the 
bioactivities of purified QUB-1439, including antimicrobial assay, anticancer assay and 
haemolysis assay. The results showed that QUB-1439 has ability to inhibit the growth of 
Gram-positive bacteria, the MIC of QUB-1439 against S. aureus is 16 µM.  QUB-1439 
does not exhibit toxicity and it has a weak effect on inhibition of cancer cell growth. 
Because QUB-1439 has these promising properties, it could be developped into a novel 
drug. 
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1.1 The source of bioactive peptide 
So far, a huge number of peptides with a variety of bioactivities peptides have been 
identified. In the Biopep database, there are more than 1500 different bioactivities 
peptides have been recorded (Moreno-Montoro et al., 2018). A majority of bioactive 
peptides come from nature, such as from plants, animals, fungi, microbes and their 
products, because in these nature source contain diverse proteins in them (Bhat et al., 
2015). However, a good deal of bioactive peptides had been found in foods as well. For 
example, an important source of the bioactive peptide in foods-- milk or dairy products. 
Milk contains a huge number of proteins; it could be divided into two group Casein and 
whey proteins. Through enzymatic proteolysis, milk proteins can be resolved into lots of 
peptide fragments, and that be regarded as the source of bioactive peptides. Milk has 
abilities to affect digestion and resist diseases that are predominant due to proteins and 
peptides in milk (Vincenzetti et al., 2017). Proteins in foods serve as nutrients, and it 
could promote health (Vincenzetti et al., 2017), thus bioactive peptides as a specific 
protein, could have an impact on human health as well. Moreover, bioactive peptides 
have a positive effect on body functions. 
 
1.1.1 Bio-peptides from marine 
More than 70% of the area on Earth is ocean which is are an abundant natural resource 
for lots of bioactive compounds in organisms. For example, fish, shellfish, molluscs and 
so on, which are important resource to promote economic and research development 
(Destoumieux-Garzón et al., 2016).  Marine organisms live in complex habitats and are 
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exposed to salinity, stress, temperature and light. Because of these special living and 
living conditions, Marine life is capable of producing large amounts of secondary 
metabolites that are not found elsewhere (Hamed et al., 2015). Moreover, since marine 
organisms live in those extreme conditions, the amino acid compositions and sequences 
of marine organisms are different from land bioactive peptides. Also, in addition, the 
number of the bioactive peptides in the marine environment surpasses the number of 
peptides on the land bioactive peptide, including Chrysophsin-1, ALP1, Arenicins-1 and 
Ogipeptins A (Wang et al., 2018). Those marine bioactive peptides contain a lot of 
biodiversity, like antioxidant activity, antimicrobial activity, anticancer activity, 
antihypertensive activity, anti-inflammatory activity, and so on, because bioactive 
peptide in the marine environment can be obtained from a variety of marine animals, 
plants, and lower organisms. The goby is a carnivorous marine animal, which could be 
found in the Black Sea, and the Mediterranean Sea. The peptides from goby have 
potential to inhibit ACE due to enzymatic protein hydrolysates which can be sourced 
from goby muscle (Nasri et al., 2013). 
 
1.1.2 Bio-peptides from snake venom  
Snake venom is a viscous, clear or light-yellow liquid that is a mixture of various toxic 
proteins, enzymes and polypeptides, and many biologically active molecules. Some 
studies have shown that many peptides isolated from snake venom have certain clinical 
value. Some natriuretic peptides were isolated from snake venoms, such as PNP 
(Pseudocerastes persicus natriuretic peptide) and TNPα (Fry et al., 2005), these can 
increase urine flow, sodium excretion and decrease blood pressure. Besides they can be 
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used in treating hypertension, peptides from snake venoms also could be used to treat 
pain and avoid the skin aged (Pennington et al., 2017). 
 
1.1.3 Bio-peptides from spider venom  
Spiders are considered as the largest clade of venomous organisms because they have a 
high species diversity, that is estimated over 39,000 species (Quintero-Hernández et al., 
2011). Spider venom could quickly help them catch prey and avoid predators. Spiders 
release venom from their paired glands. However, the paired glands of some spider 
species cannot produce venom, such as Uloboridae (Garb, 2014). Spider venom contains 
lots of complex components, such as salts, small organic molecules, peptides and proteins 
(Saez et al., 2010). However, peptides are the dominant components in the venom of the 
most spiders. According to the reports, there is an estimate of more than 10 
million bioactive peptides in spider venoms (Saez et al., 2010). These include ω-
Hexatoxin-Hv2a, ω-Plectotoxin-Pt1a and ω-Theraphotoxin-Hh2a (Windley et al., 2012).  
Most peptides possess rich disulfide bonds and are relatively short peptides. Some the 
peptides possess disulfide bonds with the specific arrangement, and this unique 
arrangement provides those peptides with abilities to resist proteases. Apart from the 
resistance to proteases, spider venom peptides also are found to possess other biological 
activities, such as insecticidal activity, antiarrhythmic, antimicrobial and analgesic 
properties (Saez et al., 2010). 
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1.1.4 Bio-peptides from scorpion venom  
Some data showed that the existence of Scorpions dates back over 400 million years ago. 
Thus scorpions can be considered as one of the oldest animals around the world 
(Quintero-Hernández et al., 2015). Some studies demonstrated that nearly 15,000 species 
of scorpions live on the planet (Luna-Ramirez et al., 2017), and they distribute in the 
different areas in the world. At the end of the scorpion telson, there are specific venom 
glands, which produce toxin secretion (Soliman et al., 2013). These toxin secretions 
could help them to defend themselves against predators and capture prey.  
Scorpion venoms are rich sources of biologically active peptides that are classified into 
disulfide-bridged peptides (DBPs) and non-disulfide-bridged peptides (NDBPs). NDBPs 
are the central scorpion venom peptides, the proportion of them are over one-third of all 
peptides within scorpion venom, such as Bs10, Hadrurin and Parabutoporin (Zeng et al., 
2005). NDBPs have been identified to that contain many biological activities, such as 
Bradykinin potentiating activity, antimalarial activities and Immune-modulatory activity 
(Almaaytah and Albalas, 2014). Scorpion venom has neurotoxic effects due to DBPs 
usually target membrane-bound ion channels. 
 
1.1.5 Bio-peptides from amphibian skin secretion 
Amphibian skin plays a vital role in amphibian’s daily life. Skin is a complex organ with 
many fundamental functions that could make amphibian adapt to a wide range of living 
environments from deep freshwater lakes to arid deserts, and it can produce abundant 
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bioactive molecules to regulate their healthy. As known, the skin secretion of amphibian 
contains lots of complex components, including peptides, proteins, alkaloids and steroids. 
A huge number of peptides have been isolated from skin secretion of amphibians. The 
skin secretion of frogs and toads is an abundant source of the biologically active peptide, 
in particular, these anurans that come from Hylidae and Ranidae families. AMPs belong 
to Hylidae family, including dermaseptin-S1, Frenatin 2.1S, Dermatoxin and Phylloxin. 
Brevinin-1 E, Esculentin 1B, Gaegurin-5 and Temporin G are the member of Ranidae 
families of antimicrobial peptides (Vanhoye et al., 2003). 
 
1.2 The function of bioactive peptides  
A considerable number of bioactive peptides has been identified, and they usually contain 
2 to 20 amino acid residues (Mirzapour et al., 2017). These peptides contain a variety of 
bioactives, including antihypertensive, antidiabetic antioxidant, and antimicrobial. 
According to reports, the function of peptides is usually based on their structures, amino 
acid sequences and hydrophobicities (Mirzapour et al., 2017).  
1.2.1 Antidiabetic Peptides  
Diabetes is a normal disease in modern society and that belongs to metabolic diseases. 
People who suffer from diabetes have high blood sugar levels, because of insulin release 
deficiency or inadequacy in insulin action.  
Diabetes is divided into two types, type I and type II. Type I diabetes leads to beta cells 
of the pancreas to release little or no insulin, type II diabetes is due to insulin secretion, 
  7 
and blood sugar absorption is in imbalance. According to studies, a lot of peptides from 
natural sources have been identified to have an activity to treat and control diabetes. For 
instance, antidiabetic peptides from fermented soybean, which have been reported to 
have the ability to enhance glucose-stimulated insulin secretion and prevent insulin 
resistance (Kwon et al., 2011). Moreover, peptides generated from black bean protein 
hydrolysates shown they block glucose transporter GLUT2 and SGLT1 to decrease blood 
glucose levels. These bioactive peptides usually treat diabetes by modulating molecular 
targets of diabetes. For example, they inhibit α-glucosidase and dipeptidyl peptidase IV, 
promote insulin secretion, reduce glucose absorption in the gut and improve blood 
glucose uptake in peripheral tissues (Mojica et al., 2017). 
 
1.2.2 Antioxidant Peptides 
Oxidation is a risk factor in human life which is likely to cause diseases, for example, 
diabetes, cardiovascular diseases, and neurodegenerative disorders (Rahman, 2007). The 
hydrolysates of soy protein acquire strong antioxidant activities and, many reports have 
shown that the antioxidant activities were obtained by plants and animals protein 
hydrolysation (Sun et al., 2011), the isolation of these protein hydrolysates could produce 
antioxidative peptides and, most of these peptides consist of 5-16 amino acid residues 
(Moure et al., 2006). 
Also, frog skins contain antioxidant peptides. Unlike other vertebrates, amphibians are 
more likely to suffer non-biological damage because their skin is exposed to air or water. 
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Skin helps frogs to oxygen uptake, however, when the oxygen concentration is higher, 
most of the oxygen will be consumed by skin only, which leads to a lack of satisfaction 
of the oxygen needs of other tissues (Liu et al., 2010). This condition will cause ROS 
(reactive oxygen species) injury which is a significant, unavoidable injury (Halliwell et 
al., 1997). The function of the antioxidant peptides in frog skins is to protect frog from 
an injury from ROS. These peptides can immediately scavenge free radicals; the ability 
to rapidly eliminate is a peculiar property of amphibian skin antioxidant peptides (Yang 
et al., 2009). 
 
1.2.3Antihypertensive peptide 
Cardiovascular disease is a common sickness, lots of adults in the world are suffering 
from this disease. Hypertension is one of cardiovascular disease, and high blood pressure 
is the risk factor to increase the possibility of suffering from coronary artery disease, 
stroke, heart failure and other cardiovascular diseases (Franklin and Wong, 2013).  
Many studies have shown that lots of bioactive peptides from nature source have 
potential to fight hypertension, such as isolating peptides from sea cucumber gelatine, 
scorpion and goby. Bradykinin is one of these bioactive peptides, which plays an 
essential role in regulating blood pressure. The function of bradykinin is to improve 
vasodilatation and permeability of capillaries, as results, blood pressure decreased. Also, 
these bioactive peptides can inhibit ACE (Angiotensin I-converting enzyme), which play 
a vital role in the RAS (Renin-angiotensin system). RAS is responsible for adjusting fluid 
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homeostasis and human blood pressure. Inhibition of ACE is essential in treatment 
because  it inactivates vasodilators (Mirzapour et al., 2017). 
 
1.2.4 Antimicrobial peptide (AMP) 
Antimicrobial peptides are common peptides in the world, a vast number of these 
peptides have been identified and studied, some of the AMPs come from synthesis and 
others from natural sources.  
In 1939, an antimicrobial agent was extracted from a soil Bacillus strain, this 
antimicrobial agent can make mice have ability to protect from pneumococci infection. 
Then, in 1940, the first AMP was isolated from soil Bacillus strain extra, namely 
gramicidin (Hotchkiss and Dubos, 1940). Gramicidin is an effective AMP for treating 
topical wounds and ulcers, though studies have shown that the use of gramicidin in the 
abdominal cavity has certain toxicity. In the following year, tyrocidine and purothionin 
have been found respectively. Tyrocidine can potent against either Gram-negative 
bacteria or Gram-positive bacteria, but this peptide has toxicity to the human blood cell 
(Dubos and Hotchkiss, 1941). Purothionin was isolated from a plant Triticumaestivum, 
it can kill fungi and some pathogenic bacteria.  
A majority of AMPs derives from eukaryotic origins such as plants, animals, and fungi. 
They work as the first line of defence in all multicellular organisms. For example, plants 
and invertebrates lack adaptive immunity, thus they utterly dependent on the innate 
immune system to help them to against infection (Kumar et al., 2018).  So far, more than 
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500 AMPs have been found that were isolated from Amphibian skin secretin (Jenssen et 
al., 2006), which is considered as a treasure house of AMPs. Also, most of these AMPs 
exhibit rapid antimicrobial effect at high concentration as well as weak toxicity to the 
human blood cell. 
Furthermore, most of the AMPs have several common properties whether nature AMPs 
or synthetic AMPs. They possess same length, positively net charge and they are 
hydrophobic (Le et al., 2015). Although antimicrobial peptides possess lots of similar 
properties, there is a significant difference between them. Some of them target on 
microorganisms not to the normal cell, however, others target on microorganisms and 
normal cell (Kohanski et al., 2010). AMPs are a kind of natural compounds which plays 
a significant role in the innate immune system (Zasloff, 2002). AMPs have selectivity 
and mainly target on the bacteria cell membrane without harming the normal cell 
membrane. Most of the antimicrobial peptides possess cationic amino acids so they can 
regonise the negatively-charged lipids on the cell surface target by electrostatic 
interaction. While the normal mammalian cells contain zwitterionic phospholipids in 
their cell membrane (Chen et al., 2005). AMPs induce the disintegration of a cell by 
rupture of the cell wall and membrane that exhibit potent activity against a wide-ranging 
of microorganisms (White et al., 1995). Because of the special mechanism of AMPs, this 
type of peptides is seldom to induce microbial produce resistance. These natural 
antimicrobial peptides, like some from amphibians, are recognized as a promising 
candidate for the development of therapeutic medicines, such as anticancer, anti-viral and 
immunomodulatory agents (Conlon et al., 2014).  
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AMPs always possess a broad activity, such as anti-cancer, anti-viruses, kill bacteria and 
fungi. AMPs are mainly deployed as an antibiotic by insects and plants to protect against 
potential pathogenic microbes. Therefore, AMPs play a crucial role in innate immunity 
(Lewies et al., 2015). 
1.2.4.1 The other functions of AMPs 
Anticancer activity 
An increasing number of studies have illustrated that some AMPs which contain cationic 
amino acids, are toxic to bacteria cell but not toxic to normal, show broad-spectrum of 
anti-tumour activity. AMPs have cytotoxic activity against cancer cells, mainly because 
of the electrostatic interaction between the cationic antimicrobial peptides and the 
negative charger of a cancer cell, this interaction is significantly for AMPs selective 
disruption of cancer cell (Hansen et al., 2012). Antimicrobial peptides which have ability 
to kill the cancer cell, named anticancer peptides (ACPA), these peptides usually consist 
from 5 to 50 amino acid residues (Li and Wang, 2016). The secondary structure of 
anticancer peptides mainly is α-helical or β-sheet. The necrosis of the cell membrane-
lytic effect and non-membranolytic are the mechanism of the action of these peptides 
(Gaspar et al., 2013). 
Anti-viral activity 
A growing number of AMPs have been found that they have potential properties against 
viral pathogens , such as inhibited Influenza A virus(Hsieh and Hartshorn, 2016), human 
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immunodeficiency virus (HIV-1) and herpes simplex virus types 1 (HSV-1) and 2 (HSV-
2) (Carriel-Gomes et al., 2007).These discoveries have proved the importance of natural 
AMPs as antiviral agents. Antiviral AMPs integrate viral envelope or integrating host 
cell membrane that makes the viruses loss activity. Anti-viral peptides have the capacity 
to interdict the virus attach to the host cell, block the fusion of cell membrane and viral, 
that protect against viral infect host cells. Moreover, they could inhibit the viral 
multiplication at the very early stage of multiplication cycle (Vigant et al., 2015). 
 
1.3 The structural characterisation of AMPs  
As known, AMPs are derived from multitudinous nature sources such as bacteria, fungi, 
insects, invertebrates and vertebrates. In general, AMPs possess common feature to 
maintain their biological activity, such as charge, conformation, hydrophobicity, 
amphipathicity. Moreover, these characteristic allow antimicrobial peptides to attach to 
and insert into membrane surface to form pores through ‘barrel-stave’, ‘carpet’ or 
‘toroidal-pore’ mechanisms (Brogden, 2005). 
 
1.3.1 Charge 
Net charge is one of the significant factors of antimicrobial peptides. Some evidence 
illustrated that most of the antimicrobial peptides are cationic peptides. They carry net 
positive charges, especially those from natural sources. AMPs have the capacity to 
interact with bacteria membrane lipids because AMPs can attach to the negatively-
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charged cell surface of bacteria through electrostatic interaction (Sitaram and Nagaraj, 
1999). AMPs that carry more positive net charges show the more effective activity 
against bacteria (Jiang et al., 2008). However, when the charges exceed a threshold, 
haemolytic activity can be increased as well (Jiang et al., 2008). Thus, there may have a 
close relationship between cationic charge and biological activity. Margitta et al. 
enhanced the peptide charge from +3 to +5 and kept appropriate structural features, like 
hydrophobic properties in order to study the relationship between cationic charges and 
bioactivity. The result showed that both antimicrobial activity and selectivity were 
improved (Dathe et al., 2001). 
 
1.3.2 Conformation 
Collection antimicrobial peptides database (CAMP) have shown that there are 682  AMP 
that show high-resolution secondary structures (Waghu et al., 2014). Based on those 
structures, AMPs can be divided into four structural groups: helical peptides, β-
strand/sheet peptides, mixed helical/sheet peptides and extended non-helical/sheet 
peptides (Figure 1.1) (Mojsoska and Jenssen, 2015). Conformation of AMPs usually 
refers to the secondary structures, which plays a vital role in the interaction between 
AMPs and cell membrane. The formation of such structures can provide the “hinge 
domain”, the “anchor” and other functional segments to facilitate the insertion, 
translocation and disruption of bilipid structure (Bogdanov et al., 2014).  Most of the 
antimicrobial peptides adopt α-helical structure, antimicrobial peptides take α-helical 
structures more likely to enhance interaction with membranes and assist membrane lysis 
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(Epand and Vogel, 1999). In addition, some reports illustrate that AMPs, which contain 
high proportion of helical content, show stronger potency against bacterial strains. Also, 
helical parts of AMPs affect the toxicity against mammalian cells (Javadpour et al., 1996). 
On the other hand, β-strand/sheet peptides also possess membrane lysis ability due to the 
amphipathicity formed by the strand structure. For example, human β-defensin (HβD-3) 
activate the induction of hydrolases, which degrade the cell wall or interfere with the 
distribution of lipids in the two leaflets of the bilayer. As a result, the integrity of cell 
membrane could be effected (Dhople et al., 2006). 
 
 
Figure 1.1 Secondary structures of antimicrobial peptides, including   helical peptides, β-
strand/sheet peptides, mixed helical/sheet peptides and extended non-helical/sheet peptides 
(Wikipedia, 2018; https://goo.gl/images/1GBkXo). 
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1.3.3 Hydrophobicity 
Hydrophobicity is vital for AMPs to interact with membranes because the responsibility 
of hydrophobicity is to control the degree of which peptides can be distributed in the 
membrane. The mechanism of the majority of cationic peptides is to disrupt the microbial 
plasma membrane, the action of the mechanism is divided into two critical steps. The 
first step is membrane binding that mainly governed by electrostatic interactions. The 
second is membrane insertion or membrane permeation, that is associated with the 
hydrophobicity of the peptide (Shai, 1999). In general, almost half of the residues exist 
in AMPs are hydrophobic. Moreover, biological activity increased with increasing 
hydrophobicity; this trait is similar to charge (Chen et al., 2007). It is reported that 
antimicrobial peptides contain the medium extent of hydrophobic as increasing degree of 
hydrophobic are correlated with mammalian cell toxicity and loss of antimicrobial 
activity (Edwards et al., 2016). There is a threshold in the content of hydrophobicity. 
Normally, antimicrobial activity increase with increasing the content of hydrophobicity, 
but if the content of hydrophobicity over the limit, that will produce toxicity to 
mammalian cell and antimicrobial activity reduced (Yin et al., 2012).  
 
1.3.4 Amphipathicity 
As the previous mention that charge, conformation and hydrophobicity are essential for 
antimicrobial peptides, they are relative to the bioactive of AMPs. Except for these 
factors, Amphipathicity also is essential for AMPs. Almost all of the antimicrobial 
peptides have amphipathicity feature, and it could be formed by a lot of different peptide 
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structures (Ebenhan et al., 2014). The most common feature is amphipathic α-helix, that 
is best for interaction with amphipathic biomembranes. The majority of antimicrobial 
peptides build amphipathicity structures upon AMPs interact with target cell membranes 
(Ebenhan et al., 2014). Amphiphilic indicates the relative proportion and polarization of 
hydrophobic and hydrophilic regions in peptides. 
 
1.3.5 Pore-formation mechanisms of AMPs on bacteria cells. 
According to studies, different antimicrobial peptides have different target sites and 
different activity mechanisms insert into the cell membrane, forming pores in the cell 
membrane and splitting cells to kill bacteria. For example, Magainin, which binds to the 
cell surface, Buforin-2 that enters the cell and colonizes the bacterial cytoplasm (Brogden, 
2005). Studies have shown that peptides bind to cells in two different physical states: at 
low peptide/lipid ratios, peptides bind in parallel to lipid bilayers; at high peptide/lipid 
ratio, peptide molecules are vertically oriented and inserted into lipids (Yang et al., 2001). 
Transmembrane pores are formed in the bilayer. Nowadays, many models are used to 
explain membrane permeation, for example, "barrel-stave model", "carpet-model" and 
"toroidal model" (Chan et al., 2006). In the "barrel-stave model" (Figure 1.2 A), peptides 
helics constitute a bundle in the membrane with a central cavity, which is similar as a 
barrel constructed of helical peptides as the staves. Peptides cross the cell membrane and 
form a hole filled with peptides. In the "carpet-model", peptides directional parallel (“in-
plane”) to the surface of the membrane ((Figure 1.2 B), the peptide is electrostatically 
attracted to the anionic phospholipid head group at multiple sites on the surface of the 
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cover membrane in a carpet-like manner. This is followed by a detergent-like action 
caused by the peptide, leading to pore formation. In the "toroidal model" ((Figure 1.2 C), 
the antimicrobial peptide is helically inserted into the membrane and induces the lipid 
molecules to bend continuously inwards towards the pore, allowing the water core to be 
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Figure 1.2 Three models of the mechanisms of antimicrobial peptides(Oren and Shai, 1998). 
The barrel-stave model of antimicrobial-peptide-induced killing(A). The carpet model of 
antimicrobial-induced killing (B). The toroidal model of antimicrobial peptide-induced killing 
(c).  
Available at: https://www.nature.com/articles/nrmicro1098 
 
1.4 Temporin 
A family of amphibian antimicrobial peptide, first extracted from the European red frog 
Rana temporaria, named temporins (Simmaco et al., 1996). So far, temporins are the 
smallest antimicrobial peptides, with a length consist from 10 to 13 amino acids and a 
conserved sequence (Mangoni, 2006). Moreover, they contain an amide bond at the C-
terminal end and exhibit a weak cationic charge, because temporin family AMPs 
generally contain less positively charged amino acids. For example, their sequences 
contain one or two lysine or arginine. In addition, temporin peptides have been found 
only in the amphibian species up to the present day. 
Similar with most of antimicrobial peptides, temporins can adopt an amphipathic α-
helical structure in hydrophobic environments. Since perturbing the integrity of cell 
membranes leads to inhibition of cell growth and death action. Up to now, nearly 40 
family members of temporins have been isolated and identified, the variation of peptide 
chain length and structure between members is quite large, and the activity is diverse 
(Haney et al., 2009). According to research, the majority of temporin family 
antimicrobial peptides against gram-positive bacteria. However, some temporin AMPs 
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have broad-spectrum antimicrobial activities, they have ability to kill gram-positive 
bacteria, gram-negative bacteria and fungi (Giacometti et al., 2006) and they are not toxic 
to normal mammalian cells (Mangoni, 2006).  
 
1.5 Aims 
1. A skin secretion-derived cDNA library from Hylarana guenheri was constructed and 
further subjected to “shotgun” cloning to obtain the full-length biosynthetic precursors 
encoding cDNA.  
2. Bioinformatics analysis was employed to determine the similarity between nucleotide 
and translated open reading frame amino acid sequences primary and the published 
sequences in the database.  
3. Solid phase peptide synthesis is carried out to obtain large quantities of replicates of 
mature peptide, which were further purified by RP-HPLC and analysed by MOLDI-TOF. 
4. Biological activity of the synthetic peptide were evaluated by antimicrobial, anticancer 
and haemolytic assays.  












Chapter 2 Materials and methods 
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2.1 Specimen biodata and secretion harvesting  
Chinese frog (Hylarana guentheri) was settled in a purpose-designed amphibian facility 
which was similar to its original habitat. The frog was fed with vitamin-rich/mineral-rich 
crickets every two to three days for at least four weeks. The skin secretion was obtained 
by using a transdermal electrical stimulation technique, which was gentle electrical 
stimulation to the dorsal skin. The harvested secretion was washed from the skin by 
distilled deionised water and collected into chilled glass beakers. Then the harvested 
secretion was snap-frozen in liquid nitrogen and lyophilised. The lyophilisate was stored 
at –20°C before being analysed. 
2.2 Shotgun Cloning 
2.2.1 mRNA isolation from lyophilised Hylarana guentheri skin secretion 
A Dynabeads® mRNA DIRECT™ Kit (BIOTECH, UK) was used to isolate 
polyadenylated mRNA from the lyophilised skin secretion. Five mg of lyophilised Rana 
Hylarana guentheri skin secretion was stored in a 1.5 ml tube and then dissolved in 1 ml 
Lysis/Binding buffer. Afterwards, the contents was mixed thoroughly by shaking on a 
vortex for 1 minute. Then, the tube was placed on ice for 3 minutes to cool down. The 
shaking and cooling cycle was repeated for four times, after which was 5-minute, 18000 
×g centrifugation to collect the clear sample lysate. The supernatant was kept in an ice 
bath until the beads were ready for use. 
Thoroughly-resuspended 250 µl Dynabeads® Oligo (dT)25 beads (5 mg/ml) were 
transferred into a 1.5 ml RNase-free tube, after which the tube was placed on a magnetic 
rack. After discarding the storage buffer completely and removing the tube away from 
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the magnetic rack, 250 µl of Lysis/Binding Buffer was transferred into the tube to wash 
the beads by gently shaking, followed by abandoning the buffer in the same practice.  The 
clear sample lysate was transferred into the tube containing prepared beads, and the 
mixture of which was blended by slowly shaking for 15 min at room temperature for full 
hybridisation between the poly-A tail mRNA and oligo-dT beads. After binding, the tube 
was placed on the magnetic rack again to remove the supernatant and the remaining beads 
combined with mRNA were washed three times with 500 µl Washing Buffer A and then 
twice with 500 µl Washing Buffer B. 18 µl of Tris-HCl (10 mM) elution buffer was 
added dropwise to the tube at room temperature. Then the tube was incubated in a heating 
block at 80°C for 2 min and immediately placed on a magnetic rack directly after 
incubation. The supernatant containing the desired mRNA was carefully transferred into 
a new RNase-free 0.2 ml tube and placed on ice immediately. 
2.2.2 cDNA library construction 
A BD SMART™ RACE cDNA Amplification Kit (BD Bioscience Clontech, UK) was 
used to accomplish the first-strand cDNA synthesis. Full length cDNAs were generated 
in reverse transcription reactions through the joint action of BD SMART™ A 
Oligonucleotide and novel BD Power Script™ Reverse Transcriptase (RT). Different 
reagents were prepared and added to new 0.2 ml tubes as shown in Table 2.1. 
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Table 2.1 The components of different reagents of 3’- and 5’-RACE ready cDNA 
library construction.  
5’-RACE ready cDNA 3’-RACE ready cDNA 
3 μl sample 4 μl sample 
1 μl 5’ CDS primer (12 μM )* 1 μl 3’ CDS primer (12 μM )** 
1 μl SMART II oligo (12 μM )***  
 
*3’-CDS Primer sequence: 5'–AAGCAGTGGTATCAACGCAGAGTAC(T)30V N–3' 
(N = A, C, G, or T; V = A, G, or C) 
**5’-CDS Primer sequence: 5'–(T)25V N–3' (N = A, C, G, or T; V = A, G, or C) 
*** SMART Ⅱ oligo sequence: 5'–AAGCAGTGGTATCAACGCAGAGTACGCGGG–
3' 
 
All the tubes were centrifugated briefly, incubated at 70°C for 2 min and cooled on ice 
for 2 min. The master mix (Table 2.2) was added to each tube and mixed completely, 
after which briefly centrifugation was applied to collect all the contents to the bottom of 
the 0.2 ml tubes without bubbles. After adding all the reagents, these tubes were 
incubated at 42 °C for 1.5 h in a thermal cycler (Applied Biosystems, UK). Then, 50 µl 
PCR-grade water was added into each tube, followed by an additional incubation at 72 ℃ 
for 7 min in the thermal cycler. Finally, constructed cDNA libraries were harvested and 
stored at -20 °C for further study up to three months. Table 2.2 The components of master 





Reagent Final Volume Final Concentration 
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5 × First-strand Buffer 2 µl 1 × 
DTT (20 mM) 1 µl 2 mM 
dNTP Mix (10 nM) 1 µl 1 mM 
BD RTase (100 Unit/µl) 1 µl 10 Unit/ µl 
2.2.3 Rapid Amplification of cDNA Ends PCR (RACE PCR) 
According to the manufacturer's instructions, BD SMARTTM RACE cDNA amplification 
kit (Clontech, UK) was used in this procedure. The sense primer used here was designed 
based on the highly-conserved domain at the 5’-untranslated region of cDNA from the 
closely-related species, and antisense primer was the Nested Universal Primer (NUP) 
provided with the kit. 
Table 2.3 The components of one RACE-PCR reaction. 
Reagent Volume Final concentration 
PCR-Grade Water 3.1 µl - 
10 × BD Advantage 2 PCR Water 1.5 µl 1.5 × 
dNTP Mix (10 mM) 0.2 µl 0.2 mM 
NUP (20 µM) 0.5 µl 1 µM 
Sense Primer (20 µM)  0.5 µl 1 µM 
50 × BD Advantage 2 Polymerase 
Mix 
0.2 µl 1 × 
3’-RACE ready cDNA library * 5 µl - 
* 3’-RACE ready cDNA library was substituted with the same volume of PCR water in 
the negative control group. 
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The tubes were centrifuged briefly to collect all contents at the bottom without bubbles. 
Afterwards, all tubes were put into the thermal cycler by the following PCR cycles (Table 
2.4). The products were stored at 4°C. 
Table 2.4 The cycles of RACE PCR programme 
Stage Temperature Time 
Stage1 (Initial Denaturation) 94 ℃ 1 min 
Stage 2 (Denaturation) 94 ℃ 20 s 
(40 cycles) 55 ℃ 10 s 
 60 ℃ 4 min 
Stage 3 (Final Extension) 72 ℃ 10 min 
 
2.2.4 Gel electrophoresis for analysing RACE PCR products 
In order to analyse RACE PCR products, 0.45 g agarose powder (Invitrogen, UK) were 
mixed with 35 ml of freshly prepared 1 × Tris/Borate/EDTA (TBE) buffer (Invitrogen, 
UK) in a conical flask, followed by heating to dissolve the agarose. After the liquid 
cooling to about 40 °C, 2.5 µl 10 mg/ml Ethidium Bromide (EB) (Sigma-Aldrich, USA) 
was added to the melted agarose. Afterwards, the melted agarose was poured into a tank 
with one comb inserted, waiting for the mixture to solidify. After the solidification of the 
agarose gel, with the comb was taken away and the tank was filled with running buffer 1 
×TBE Buffer. 2.5 µl of 100 bp DNA ladder (0.5 µg/lane; Biolabs, UK) was loaded in the 
first well, while remaining wells were loaded with 0.5 µl loading dye (Invitrogen, UK) 
and 1.5 µl RACE PCR product. The electrophoresis was run at 90 V for about 30 min 
until the dye front migrated approximately two-thirds of the way down the gel. Finally, 
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the gel was transferred to UV trans-illuminator-BioDoc-It® Imaging System (NVP, 
Nuffield Road, Cambridge, UK) for analysis. 
2.2.5 Purification of RACE PCR products 
A Cycle Pure Kit (Omega Bio-Tek, USA) was used to purify the desired PCR products. 
The DNA amplification sample was mixed with quintuple CP Buffer to a Hi-Bind® DNA 
Mini Column, followed by 15,000 × g centrifugation for 1 min. After discarding all the 
flow-through, 700 µl DNA Washing Buffer was added to the cartridge. Then, the column 
was centrifuged at 15,000 ×g for 1 min to discard the flow-through again, followed by 
an additional wash by another 500 µl DNA Washing Buffer in the same procedure. After 
washing, the column was centrifuged at 18,000 ×g for 2 min to remove the buffer 
completely. Before elution, the column was transferred to a new 1.5 ml DNase-free tube. 
Then, 30 µl PCR-grade water was added to the cartridge and the cartridge was incubated 
at room temperature for 2 min. After incubation, the column was centrifuged at 18,000 × 
g for 2 min to elute purified DNA. Finally, the DNA samples were concentrated in a 
concentrator (Eppendorf. Germany) for 1h. 
 
 
2.2.6 Ligation  
The application of molecular cloning in this project is to determine the existence of novel 
peptide-encoded transcripts in amphibian skin secretion. TA cloning was used in this 
project (Figure 2.1).  
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Figure 2.1 The technique relies upon the ability of adenine (A) and the thymine (T) on 
different DNA fragments to hybridise and they become ligated together in the presence 
of ligase. 
A pGEM®-T Easy Vector System (Promega, USA) was used in this procedure. The 
RACE PCR products with A at both ends of strand could bind to the insertion site of the 
pGEM®-T Easy Vector (Figure 2.1) through A-T base pairing. The dried DNA samples 
were resuspended in 8 µl PCR water by vortex, briefly centrifugation and put on ice to 
cool. This cycle was repeated five times for DNA preparation. The following reagents 
(Table 2.5) were added to a new 1.5 ml DNase-free tube, after which, the tube was 
incubated at room temperature for 1h and then incubated at 4°C overnight.  
Table 2.5 The components of ligation reaction. 
Reagent Volume Final concentration 
2 × Rapid Ligation Buffer 2.5 µl 1 × 
pGEM®-T Easy Vector (50 ng/µl) 0.5 µl 5 ng/µl 
Diluted PCR products 1.5 µl - 
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T4 DNA Ligase (3 Unit/µl) 0.5 µl 0.3 Unit/ µl 
2.2.7 Transformation of recombinant DNA into competent JM109 cells 
Exogenous DNA can be amplified by host cells. JM109 High Efficiency competent E. 
coli cells (> 108 CFU/ml; Promega, USA) were employed in this process. In the 
beginning, a 500 ml bottle was prepared to contain 200 ml of deionised water, and 6.4 g 
of LB agar powder (Invitrogen, UK). Then, this bottle was autoclaved. After that, 550 µl 
of ampicillin was added to the warm autoclaved LB agar mixture. Then, 11 ml of LB 
agar solution was transferred to a clear dish after LB agar solution was mix entirely. 
Afterwards, the dish was swirled in a circular motion to distribute agar entirely. 100 µl 
of 100 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) (Promega, USA) and 20 μl 
X-Gal (50 mg/ml, Promega, USA) were spread over the surface of LB plates evenly. 
Then, 2.3 µl ligation product was transferred to a 1.5 ml tube (sterile) on the ice and 
mixed with 60 µl competent E. coli cells. Then the tube was gently flicked and put on ice 
for 20 min. The heating block was set to 42°C, and then the tube was placed on the 
heating block for 47s. After that, the tube was put on ice as soon as possible for 2 min. 
Next, 950 µl of room temperature S.O.C medium was added to the tube. Then the tube 
was heated in an orbital incubator at 37°C for 2.5h. After incubation, 100 µl 
transformation suspension was spread evenly on the prepared petri dishes and all the petri 
dished were incubated upside down at 37°C overnight. 
2.2.8 Blue & white screening for positive transformations 
The colonies containing recombinant plasmid DNA were white and sampled again to 
new petri dished by drawing the continuous line resembling ‘Z’ (Figure 2.3). The new 
dishes were put upside down and incubated at 37°C overnight for further selection. 
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Figure 2.3 Each plate was divided into 18 regions and streaked with samples 
containing white colonies. 
2.2.9 Isolation of recombinant DNA from JM109 cells 
The white colonies were picked up and transferred to a new 1.5 ml tube with 20 µl PCR-
Grade. Then, after all colonies were transferred, all the tubes were put on a 100℃-heating 
block for 5 min, followed by immediately cooling down on ice for 5 min to make the 
cells fragile. Afterwards, each tube was vortexed for 30 s and centrifuged at 20,000 × g 
for 5 min to break the cell walls and release the DNA. 
 
 2.2.10 Cloning PCR 
After isolation of recombinant DNA, another PCR traction was performed, and reagents 
shown in Table 2.6 were added to each PCR reaction tube. The cloning PCR products 
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were stored in the fridge at 4°C. PCR tubes were placed into the thermal cycler and the 
programme in Table 2.7 was run. 
Table 2.6 The components of cloning PCR reaction. 
Reagents Volume Final concentration 
10 × PCR Buffer 
dNTP Mix (10 mM) 
M-13 former primer (20 µM) 
M-13 reverse primer (20 µM) 
GoTaq® Polymerase (5 Unit/µl) 
















Table 2.7 Programme of cloning PCR 
 
Stage Parameter 
Stage 1 initial denaturation at 94℃ for 1 min 
Stage 2 31 cycles (denaturation at 94℃ for 30 s, annealing at 55℃ for the 
30s, extension at 72℃ for 3 min) 
Stage 3 A final extension at 72℃ for 3 min and storage at 4℃ before use 
2.2.11 Gel analysis of cloned PCR products 
This procedure was performed as described in section 2.2.4.  
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2.2.12 Purification of cloned PCR products 
The Details of Purification of cloned PCR products as described in section 2.2.5. 
2.2.13 Sequencing reaction  
The purpose of sequencing reaction was amplifying the purified cloned PCR products 
connected with M13F/M13R.The ddNTPs was used in this PCR reactions to stop the 
extension of the new DNA chain because ddNTPs are lacking an extra oxygen atom in 
deoxyribose that was different from others PCR reaction. 
In this section, A Big Dye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, 
USA) was used for the sequencing reaction. After thawing the reagents, the sequencing 
reaction was set up in 0.2 ml tubes with reagents described in Table 2.7. 
Table 2.7 The components in each sequencing reaction tube. 
Reagents Volume Initial concentration 
PCR-Grade Water 
Diluted M13F/M13R 
2.5 × Ready reaction mix 
5 × BigDye Sequencing Buffer 












Finally, tubes were placed in the thermal cycler (ThermoFisher Scientific, USA) and 
Sequencing was run (Table 2.8). Finally, The PCR products were stored at 4°C. 
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Table 2.8 The sequencing reaction PCR programme 
Stage Parameter 
Stage 1 initial denaturation at 96℃ for 1 min 
Stage 2 26 cycles (denaturation at 96℃ for 20 s, annealing at 55 ℃ for 10s, 
extension at 60℃ for 4 min) 
Stage 3 Preservation at 4℃ for 7 min 
 
 
2.2.14 Purification of extension products. 
Ten µl of PCR-Grade water was added to each tube and then 72 µl of 95% ethanol 
(Sigma-Aldrich, USA) was added to each sequence reaction tube. Afterwards, the 
solution in the PCR tube was added to the corresponding tube without pipetting. Then, 
each tube was mixed entirely by vortexing for 30 s. These tubes were put at room 
temperature for 20 min followed by 20,000 × g centrifugation for 20 min in an Eppendorf 
Centrifuge 5424 (Eppendorf, Germany), and all supernatant was poured away rapidly. 
After that, 260 µl of 70% ethanol was added to each tube, followed by centrifugation at 
20,000 × g for 10min. The supernatant was discarded quickly, and all tubes were placed 
in a concentrator for 3 h to evaporate all ethanol. 
2.2.15 DNA sequencing 
For sequencing, 10 µl highly deionised-formamide (HiDi) (Applied Biosystems, USA) 
was added to each tube. These tubes were centrifuged briefly and then heated at 95°C for 
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4.5 min and then cooled for 3.5 min. Afterwards, 10 µl prepared sample was transferred 
to a 96-well sequencing plate. Finally, the DNA was sequenced using an ABI 3730 
automated sequencer (Applied Biosystems, USA). 
2.2.16 Bioinformatic analysis 
Chromas was applied to scan the fluorogram. Next, Protein Analysis System (ExpaSy) 
translate tool was used to translate the base sequences into protein sequence and the Basic 
Local Alignment Search Tool (BLAST) was applied to search for proteins similar to the 
sequenced product in the database of the National Centre for Biotechnology Information 
(NCBI). The similarity of the newly sequenced peptide to other known peptides in this 
way could be determined. 
2.3 Solid-phase peptide synthesis 
A TributeTM Peptide Synthesiser (Protein Technologies, USA) was used to synthesise the 
target peptide QUB-1439 efficiently. This technique requires the first amino acid to be 
attached to a polymeric resin at the C-terminus. Except for first amino, other amino acids 
were protected by Fmoc (9-fluorenylmethoxycarbonyl) groups, performing a series of 
coupling and washing steps these amino acids were transferred sequentially to this until 
the sequence was finished. 
2.3.1 Synthesis using the Tribute synthesiser 
The weights of catalyst 2-(1H-benzotriazole-1-yr)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU) and dry amino acids in equal proportion of four-fold molar 
excess, were calculated and weighed into amino acid vials. Before synthesis, 0.3mmol 
resin [weight(g) = 0.3 mmol / loading capacity (0.65 mmol/g)] was required to added 
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into the reaction vessel. 
All amino acid vials were put into precise positions for the peptide. At first, the inline 
solvent filters and the source of nitrogen were checked. DMF (N, N-Dimethylformamide), 
11% NMM (4-methyl morpholine) in DMF and 20 % piperidine in DMF were required 
for synthesis. 
The start and the stop positions on the carousel as well as the appropriate coupling 
programme for each amino acid were selected. The peptide synthesiser was run with the 
major programme as shown below: 
Table 2.9 The major programme of the peptide synthesiser. 
Step Reagent Action Time Mix type Drain Repeat 






10s N2, Vortex Yes 3 




Dissolve amino acid 
Activation 
10s N2, Vortex Yes 1 
5 Amino Acid Coupling 10s / / 1 
6 / Mix / N2, Vortex Yes / 
 
2.3.2 Cleavage reaction 
After the synthesis, the washed and dried product was weighed and transferred into a 
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flask. After that, cleavage cocktail (25 ml/g), including 94% Trifluoroacetic acid (TFA), 
2% Thioanisole (TIS), 2% 1,2-Ethanedithiol (EDT) and 2% H2O, was prepared and 
transferred into the flask for cleaving the side-chain protecting groups and resin at the 
room temperature for 2 h. The cleavage mixture was transferred into a new flask by the 
Buchner funnel. Finally, the remaining solution was added into a 50 ml tube, and 45 ml 
Et2O was added for peptide precipitation at -20°C overnight. 
 
2.3.3 Washing and lyophilisation 
These products tubes were taken out from the freezer, then centrifuging these tubes at 
2500 × g for 5 min to collect the precipitated peptide. Then, Et2O was added to 50 ml in 
the tube after the supernatant was decanted carefully and this washing step was repeated 
three times. Next, the evaporation of the Et2O took place in a vacuum desiccator with the 
covering foil pierced by a needle. 10 ml Solution A (0.05%TFA, 99.95%H2O) was added 
to dissolve the dried peptide.  
The tube was then frozen in liquid nitrogen and then transferred into an Alpha 1-2 freeze-
dryer (SciQuip, UK). At last, the lyophilised peptide was weighed and placed in a freezer 
at -20 °C. 
2.4 Identification and purification of peptides 
A part of the lyophilised peptide of the synthesised peptide QUB-1439 was dissolved in 
RP-HPLC Solvents A to identify and assess the purity. Further purification was 
performed by RP-HPLC. 
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2.4.1 Purification of crude peptide by Reversed-phase high performance liquid 
chromatography (HPLC) 
An analytical reverse phase HPLC Jupiter C5 column (250nm * 10 mm, Phenomenex, 
UK) was used in this process. After the self-examination of the detector, the wavelength 
of the detector was adjusted to 214 nm. Before separation, the column was washed with 
Buffer B for 30 min and equilibrated with Buffer A for 30 min and the flow rate was 4 
mL/min. Subsequently, 4 mg of lyophilised peptide was dissolved in 1mL Solution B (80% 
Acetonitrile, 19.95% H2O and 0.05% TFA) in the tube and then centrifuged at 5000 × g 
for 20 min. Then, 1 ml supernatant was loaded to the RP-HPLC column. The column was 
eluted with a linear gradient formed from 100% Solution A mixed 0% Solution B to 100 % 
Solution B mixed 0 % Solution A over 80 min at a flow rate of 1ml/min. The fractions 
were collected in polypropylene tubes (Starstedt, Germany) at every peak. Finally, the 
sample was utilised for identification. 
2.4.2 Detection of molecular weight by Matrix-assisted laser desorption ionisation 
time-of-flight mass spectrometry  
MALDI-TOF mass spectrometry was used for peptide identification. In a TOF analyser, 
a set of ions with the same amount of energy but different mass/charge ratios (m/z) are 
subjected to the same constant electric field from the MALDI plume, result showed ions 
reaching the detector at different times. At first, 10 mg CHCA was dissolved in an 
acetonitrile/H2O/TFA (50%/49.95%/0.05%, v/v/v) solution. 2 μl sample of each 
chromatographic fraction was spotted on a MALDI plate and air-dried at room 
temperature. Next, 1 μl CHCA was loaded to each dried sample spot and air-dried. The 
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plate was subjected to mass spectrometric analysis using a Perseptive Biosystems 
Voyager-DE MALDI-TOF system in positive detection mode. With the combination of 
MALDI-TOF identification and RP-HPLC isolation, a relatively pure peptide was 
obtained and subjected to subsequent bioassays. 
 
2.5 Antimicrobial activity assays  
Three different microorganisms: Staphylococcus aureus (S. aureus), Escherichia coli (E. 
coli) and Candida albicans (C. albicans), were employed in this thesis. This experiment 
was aimed for the determination of minimum inhibitory concentrations (MICs) and 
minimum bactericidal concentrations (MBCs) of the peptide towards these three 
microorganisms. MIC was defined as the lowest bacteriostatic concentration that 
inhibited the visible growth of a microorganism after overnight incubation. The MBC 
was defined as the lowest bacteriostatic concentration that killed all the cells.  
2.5.1 Inoculation of microorganisms 
One bead of each microbial culture was transferred from frozen stock into flasks of 100 
ml Mueller-Hinton broth (MHB). Subsequently, the flask was incubated in an orbital 
incubator at 37 °C for 16-20 h. 
2.5.2 Subculture of microorganisms 
For sub-culture, 500 µl of bacterial suspension from the flask was transferred to a bottle 
of pre-warmed 20 ml MHB. Next, the bottle was placed into the orbital incubator, 
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incubated at 37 °C for several hours until the sub-cultured bacteria reached their 
respective logarithmic growth phases, determining througha UV spectrophotometer to 
measure the optical density (OD) value of the sub-cultured bacteria at 550 nm wavelength.  
In Table 2.10 below, the appropriate OD values of the three kinds of microorganism 
cultures and their subculture incubation time was shown. 100 μl of sub-culture 
suspensions of S. aureus or E. coli were transferred into 19.9 ml of pre-warmed MHB 
medium and dispersed entirely in the petri dish. The volume of C. albicans sub-culture 
suspension was 2 ml, followed by transferred into 18 ml of pre-warmed MHB medium.  
Table 2.10 The appropriate OD values for the three microorganisms used. 
Microorganism Subculture time OD 
S. aureus 2.5 h 0.23 
E. coli 1.0 h 0.41 
C. albicans 2.0 h 0.16 
 
2.5.3 Determining minimum inhibitory concentrations (MICs) of QUB-1439 
MIC assay was carried out in the 96-well plate. The peptide was dissolved in PBS to 
prepare a 100-fold stock solution afterwards, and 1 μl of each peptide solution was mixed 
with 99 μl of diluted bacterial culture to get a final concentration range from 512 to 1 μM 
in two-fold dilution. In addition, 100 µl clean MHB was added in each well as the sterile 
control, while 100 µl bacteria solution was the growth control. Then, the 96-well plate 
was placed in the incubator overnight at 37°C . Finally, the absorbance in each well was 
measured by the Synergy HT plate reader (BioTek, USA) at 550 nm wavelength. 
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2.5.5 Viable cell counts 
The number of viable cells reflects dynamic changes in bacterial growth. One hundred 
microliter of the adjusted bacterial suspension was mixed with 900 μl of Phosphate-
Buffered Saline (PBS). Next, 10-fold dilutions of this were prepared including 10-1, 10-
2, 10-3, 10-4, 10-5 10-6. Afterwards, 20 µl of diluted suspensions was spotted onto the pre-
prepared MHA plate in three replications for each concentration. The MHA petri dish 
was then placed into the incubator at 37°C for 16-20 h. Then the original colony-forming 
units (CFUs) were calculated according to the following formula:  
N = (C × 10D × 50)/ 3 
Where N = cfu/L; C = number of colonies per dilution (for 3 spots); D = number of the 
1:10 dilution.  
2.5.6 Minimum bactericidal concentration (MBC) measurement 
For MBCs, 5 μl clear solution was taken from each well of the at clear concentrations, 
spotted onto a new MHA plate and then placed into an incubator at 37 °C overnight (16-
20 h). Afterwards, the MHA plate was checked for microorganism growth and found that 
the lowest concentration showed no colonies growth was considered to be the values for 
the MBC. 
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2.6 Haemolysis assay 
2.6.1 Preparation of the red blood cells 
At first, 2ml fresh horse whole blood was transferred into a 50 ml tube and centrifuged 
at 930 × g for 5 min to discard the supernatant and obtain the erythrocytes at the bottom. 
These red blood cells were washed by 30 ml PBS by gentle orbital shaking and then 
centrifuged at 930 × g for 5 min to discard the supernatant. This procedure was repeated 
until the supernatant became completely clear. Afterwards, 50 ml of sterilised PBS was 
transferred into the tube to mix with the red blood cells. Firstly, the peptide was dissolved 
in sterilised PBS to make peptide solutions from 512 µM to1 μM in 2-fold dilution. Then, 
200 µl peptide solutions at different concentrations were transferred to corresponding 1.5 
ml tubes with an equal volume of 4% erythrocyte suspension, setting as sample groups. 
Positive control group was 200 µl 2% Triton X-100 and 200 µl erythrocyte suspension. 
Negative control group was 200 µl PBS and 200 µl erythrocyte suspension.  
2.6.2 Incubation and detection  
All the tubes were incubated at 37°C for 2 h and then placed into centrifuge at 930 × g 
for 5 min. Supernatants were added into wells of a 96-well plate (Thermo Fisher 
Scientific), and the absorbance was detected at 550 nm with an ELx808TM Absorbance 
Microplate Reader (BioTek, USA) and the viability of cells was calculated according the 
formula:  
Viability % = (ODSample-ODNegative)/ (ODPositive-ODNegative) ×100%. 
  41 
2.7 Anticancer cell assay 
Four kinds of the human cell lines: H-157, MCF-7, PC-3 and U251MG, were used in this 
MTT cell viability assay. The human cell line H157 that is human non-small cell lung 
cancer cell line and human cancer cell line PC3 that is human prostate cancer cell line 
were cultured RPMI-1640 medium (Invitrogen,Paisley, UK) with 10% foetal bovine 
serum (FBS) (Sigma, UK) and 0.1% gentamicin solution; Nevertheless, the human 
neuronal glioblastoma cell line U251MG was cultured in DMEM with high glucose, 10% 
foetal bovine serum (FBS) (Sigma, UK) and 0.1% gentamicin solution (Sigma, UK) in a 
humidified 37°C chamber under 5% CO2. Squamous cell lung carcinoma cell line H157 
was cultured in Gibco®RPMI-1640 (Invitrogen, USA). 
2.7.1 Resuscitation of frozen cell lines 
The ampoule containing frozen cancer cells was removed immediately from the -80°C 
freezer storage and placed into a 37°C glass beaker which contains warm water for 
thawing by continuously agitating, followed by transferring all cells to a 50 ml centrifuge 
tube that contain 40 ml warm complete medium. The tube was centrifuged at 200 × g at 
room temperature for 5 min. After centrifugation, the supernatant was removed, then a 
volume of 5 ml complete medium was transferred to the centrifuge tube and blended well 
by gently pipetting. Then 1ml of this suspension was transferred to 75 cm2 flasks that 
containing 9 ml of complete medium. The flask was incubated at 37 °C under 5% CO2. 
The cells were cultured in the flasks until almost 90% of the flask surface area were 
covered with cells, the rate of that was determined by using an inverted microscope.  
Changing medium every 2 days, or changing medium when the pH indicator (e.g., phenol 
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red) in the medium changed colour. 
2.7.2 Subculturing and passaging of cells from a monolayer 
After the primary culture grown to confluence, the cells were sub-cultured in order to 
avoid the culture from dying. The medium was removed from primary culture, 10 ml of 
PBS solution without Ca2+ and Mg2+ was added into the flask to wash the cells, followed 
by discarding the PBS for removing any residual FBS that have possible to inhibit the 
action of trypsin. Afterwards, a volume of 1 ml 1 × trypsin/EDTA (Invitrogen, UK) 
solution was added to cover the cell monolayer, and the flask was located in the incubator 
for 5-10 min at 37 °C under 5% CO2. After incubation, the inverted microscope was 
employed in order to ensure that all the cells were detached and floating. Immediately, 9 
ml of complete medium was added to the flask to avoid active trypsin and pipetted to 
release any remaining attached cells. Next step was transferring the cell suspension to a 
sterile 15 ml centrifuge tube and centrifuged at 350 × g for 5 min. The supernatant was 
removed. Following this, the cells were resuspended in 10 ml complete medium 
dispersed by vortexing. A volume of the resultant cell suspension was added to a new 
flask and diluted to a final volume of 10 ml; then the flask was incubated at 37°C in a 
humidified environment containing 5% CO2. Changing the medium every 2 days or 
when the pH indicator in the medium changed colour. 
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2.7.3 Cell quantification 
50 µl of Trypan Blue was added to a well of a clean 96-well plate, and then an equal 
volume of cell suspension was added and gently pipetted to blend the mixture. 50 µl of 
the mixture was transferred onto the cell counting area (Figure 2.4) between the 
haemocytometer chamber and the coverslip by capillary action. Nine large squares were 
on each side of the haemocytometer. The random squares were counted by using a hand-
held counter under the inverted microscope. and the cells in each ml were determined 
using the following formula: 
Cells per ml = average number of the cells per large square × 104 × 2 (dilution factor) 
 
 
Figure 2.4: Haemocytometer counting area. 
From:http://d163axztg8am2h.cloudfront.net/static/img/24/06/4cc3c1d402e9241e8ca8b
569c576.jpg. Available from 08.03.2017 
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2.7.4 Peptide preparation 
The pure lyophilised peptide was weighed and dissolved in PBS or DMSO to make a 
stock solution with a concentration of 10-2 mol/L. Then, the peptide solution was diluted 
by adding relevant volumes of serum-free medium to achieve a range of concentrations 
of 10-4, 10-5, 10-6, 10-7, 10-8, 10-9 M. 
2.7.5 Cell seeding 
The cell suspension mixed with pre-warmed medium and the mixture was diluted to the 
final concentration of 5000 cells/100 µl (5 × 104 cells/ml) in the tray. Then, 100 µl sample 
of cell suspension were seeded in each well of the 96-well plate for cell attachment. Then, 
100 µl sample of cell suspension was seeded in each well of the 96-well plate in order to 
make sure cell attachment. Next step was the 96-well plate incubated for 24h at 37°C 
under 5% CO2. 
2.7.6 Cell starvation 
The medium was discarded, and 100 µl of the FBS-free medium was added to each well. 
Then, the plate was returned to the same condition incubator for 6 to12h to starve the 
cells. 
2.7.7 Peptide loading 
The medium applied in the second incubation was discarded, and 100 of peptide dilutions 
at each concentration were loaded in 5 replicates in the 96-well plate. The fresh FBS-free 
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medium was added to one column as a positive control and an equal volume of 1% 
DMSO solution was also added as a vehicle control. Finally, the plate was placed into 
incubation for 24h at 37°C under 5% CO2. 
2.7.8 MTT assay 
Ten µl of the MTT solution was transferred to each well. Then, the plate was placed into 
an incubator and allowed to react for 4-6 h. After the MTT and medium mix liquor were 
obliterated, 100 µl of DMSO solution was added to each well. The plate was placed in a 
shaking incubator for 10 min. The Synergy HT reader (BioTek, USA) was used to 
measure the coloured solution at 590 nm. The Statistical results were analysed by using 
the GraphPad Prism 5.0 software, and the result was considered to be statistically 
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3.1 “Shotgun” cloning of novel peptide precursor-encoding cDNA 
By means of shotgun cloning, the nucleotide sequence of a novel peptide precursor-
encoding cDNA was consistently cloned from the cDNA library of Hylarana guentheri 
skin secretion (Figure 3.1). The prepropeptide encoding cDNA contains 320 nucleotides, 
of which the translated open reading frame consists of 62 amino acid residues. The 
prepropeptide can be divided into three topological domains. The putative signal peptide 
is the first peptide domain at the N-terminus that contains 22 amino acid residues, most 
of which are hydrophobic. After this, the second domain is called as the acidic spacer 
peptide due to be rich of acidic amino acid residues, such as Asp and Glu, constituted by 
25 amino acid residues. Finally, the mature peptide sequence is constituted by 13 amino 
acid residues, and the following -GK- is a donor for Leu amide at the C-terminus. The 
mature peptide was named as QUB 1439 due to the computational molecular weight of 
the putative mature peptide.  
NCBI-BLAST was used to compare the full-length precursor peptide sequence with the 
previously identified frog skin defensive peptides. The results turned out that the signal 
peptide domain and the acidic spacer peptide domain are highly-conserved among the 
bioactive peptides from Rana species. As the data shown, those peptide domains of QUB-
1439 precursor are of high identity to which of brevinine peptides from the same species 
(Figure 3.2A). Additionally, when comparing the mature peptide sequences with other 
temporins, we found that QUB-1439 has been identified from this species before, which 
was named as temporin-GH (Figure 3.2B). However, neither the cDNA or the peptide 
precursor of temporin has been reported so far. Therefore, it is the first time to identify 
the encoding cDNA of QUB-1439 from the skin secretion.    
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Figure 3.1 Nucleotide sequence and corresponding open-reading frame of the QUB-1439 peptide 
precursor encoding cDNA cloned from an Hylarana guentheri skin secretion-derived cDNA library, 
Putative signal peptide is double-underlined, deduced mature peptide is single-underlined and the stop 
codon is indicated by an asterisk. 
 
 
         
BR2GB      MFTMKKSLLLLFFLGTVSLSLCEQERGADEDDGGEMTEELKRGVITDALKGAAKTVAAEL 60 
BR2GC      MFTMKKSLLLLFFLGMISLSLCEQERGADEDEGE-VEEQIKRS-IWEGIKNAGKGFLVSI 58 
QUB1439    MFTLKKTLLLLFFLGTINLSLCEQERNADEEERRDGDDQGAVEV--D------KRFLPLL 52 
           *** ** ********   ******** ***      
 
BR2GB      LRKAHCKLTNSC-- 72 
BR2GC      LDKVRCKVAGGCNP 72 
QUB1439    FGAIS-HLLGK--- 62 
                            
 
 
QUB1439    FLPLLFGAISHLLa 13 
TEMP_SYLGU FLPLLFGAISHLLa 13 
TEM1PE     FLPIVAKLLSGLLa 13 
            
B 
BR2GB      MFTMKKSLLLLFFLGTVSLSLCEQERGADEDDGGEMTEELKRGVITDALKGAAKTVAAEL 60 
BR2GC      MFTMKKSLLLLFFLGMISLSLCEQERGADEDEGE-VEEQIKRS-IWEGIKNAGKGFLVSI 58 
QUB1439    MFTLKKTLLLLFFLGTINLSLCEQERNADEEERRDGDDQGAVEV--D------KRFLPLL 52 
           *** ** ********   ******** ***      
 
BR2GB      LRKAHCKLTNSC-- 72 
BR2GC      LDKVRCKVAGGCNP 72 
QUB1439    FGAIS-HLLGK--- 62 
                          
 
 
QUB1439    FLPLLFGAISHLLa 13 
TEMP_SYLGU FLPLLFGAISHLLa 13 
TEM1PE     FLPIVAKLLSGLLa 13 
            
A 
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Figure 3.2 The amino acid alignments of (A) the full-length translated open reading 
frame amino acids between QUB-1439 and two brevinine peptides, Brevinin-2GHb 
(BR2GB, accession No. A0AEI5) and Brevinin-2GHc (BR2GC, accession No. A0AEI6), 
isolated from the same species, and (B) the mature peptide sequences between QUB1439 
and two temporin peptides, temporin-GH (TEMP_SYLGU, accession No. P84858) and 
temporin-PE (TEM1PE, accession No. A0A2H4WAJ8). The asterisks indicate identical 
amino acid residues in each sequence. 
 
3.2 The prediction of secondary structure  
In order to validate the secondary structure of QUB-1439, the I-TASSER software was 
employed to predict the secondary structure of QUB-1439. The result shows that QUB-
1439 possesses high proportion of α-helical structure (Figure 3.3A). The confidence is 
pretty high from position 4 to 12, and the 3D structure modelling shows QUB-1439 is 
able to form well-characterised helical structure (Figure 3.3C). Therefore, we conducted 
the prediction of helical wheel plot and the result shows that QUB-1439 possesses a 
hydrophobic surface as FLLILLF (Figure3.3D). In the helical structure, the 
hydrophilicity and the hydrophobic moment of QUB-1439 is 1.154 and 0.502, 




    A 










              
 
 
Figure 3.3 The secondary structure analysis of QUB-1439 by I-TASSER and Heliquest. (A) the 
prediction of secondary structure of QUB-1439, (C) 3D modelling of QUB-1439, and (D) helical 
wheel projection of QUB-1439; (B) physicochemical properties of QUB-1439. 
 
3.3 Chemical Synthesis and Isolation Identification of QUB-1439 
The crude peptide QUB-1439 was analysed by MALDI-TOF after chemical synthesis 
and the MS spectrum indicates that the peptide synthesis was successfully achieved as 
B 
C D 
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the ion with mass of 1441 Da was observed (Figure 3.4A). However, there are some 
impurities in the synthetic peptide. Therefore, RP-HPLC was carried out to purify QUB-
1439. The fraction from HPLC was subjected to MALDI-TOF analysis for determining 
the retention time of QUB-1439, which is around 74 min (Figure 3.4B). The MS spectrum 
shows that the corresponding HPLC fraction is of high degree of purity (Figure3.4 C).  
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C 
 
Figure 3.4 The MALDI-TOF MS analysis and chromatography of the QUB-1439. (A) The MS spectrum of crude peptide QUB-1439 with the observed ion of 1441.7 
Da. (B) The chromatogram of crude peptide QUB-1439 in 80 min. The retention time of QUB-1439 is indicated by an arrow. (C) The MS spectrum of collected 
fraction at the retention time of QUB-1439. The mass of observed ion is 1438.7 Da. 
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3.4 Antimicrobial activity assay of QUB-1439 
QUB-1439 is able to inhibit the growth of the Gram-positive bacteria S. aureus, while it cannot 
kill the bacteria. The MIC of QUB-1439 against S. aureus are 16 µM. QUB-1439 demonstrates 
a weak efficacy against Gram-negative bacteria E. coil and pathogenic yeast C. albicans at high 
peptide concentration, while no MICs and MBCs can be determined (Figure 3.5). The summary 
of MICs and MBCs of QUB-1439 against three microorganisms are shown in Table 1.  
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Figure 3.5. The antimicrobial activity of QUB-1439 against E. coli (A), C albicans (B) and S. aureus (C). 
The “G” and “V” represent the growth control and vehicle control, respectively. The percentage of cell 






  57 
Table 1. MICs and MBCs of peptide QUB-1439 against three microorganisms. 
Peptide 
MIC(µM) MBC(µM) 
S. aureus E. coli 
C. 
albicans 





16 >512 >512 >512 >512 >512 
 
 
3.5 Haemolytic activity of QUB-1439 
The degree of the haemolysis of the synthetic peptide QUB-1439 on horse erythrocytes is low. 
QUB-1439 induces 5% of haemolysis up to the highest concentration of 512 µM. Meanwhile 
it cannot produce any haemolytic activity at 16 µM, which is the MIC against S. aureus (Figure 
3.6).  
H a e m o ly tic  a c t iv i ty  o f  Q U B -  1 4 3 9

































Figure 3.6 The haemolysis activity of QUB-1439 against horse blood cells. The 100% of haemolysis was 
measured by the haemolytic effect of positive control (P), 1% TritonX-100. Each experiment was repeated 
three times. 
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3.6 Anti-cancer assay                     
Although four human cancer cell lines, H-157, MCF-7, PC-3 and U251MG were employed, 
QUB-1439 exhibited no anticancer activity against them at the concentration of 10 µM (Figure 
3.7).  
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Figure 3.7 The cell viability of four human cancer cell lines, H-157, MCF-7, PC-3 and U251MG, in the 
treatment of QUB-1439 at a concentration of 10. The blank control employed the cells without treatment of 
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4.1 Importance of study on temporin peptides 
Currently, the development of medicine is rapidly arriving a crossroads in regard to clinical 
applications of antibiotics. The treatment of bacterial infectious agent faces a challenge because 
of the "superbugs" quickly appeared due to the inappropriate use of conventional antibiotics 
(Council, 2006). Temporin is one of the antimicrobial peptide families discovered from genus 
Rana. As temporins usually comprise basic amino acid residues, they possess positive charge 
at the physiological pH (Mishra et al., 2018). Moreover, temporins also contain a certain 
proportion of hydrophobic amino acid residues and an α-amide at C-terminus. In addition, the 
mechanisms of temporins peptides are similar to which of other antimicrobial peptides that 
they are able to disrupt cell membrane, in which way the microorganisms are difficult to 
produce resistance to AMPs (Aoki and Ueda, 2013).  
 
4.2 Discoveries in this study 
In the study, we successfully discovered a temporin encoding cDNA from the skin secretion of 
Hylarana guentheri. Although the study of skin defence peptides from this species was initiated 
12 years ago, there are only five peptides derived from same species that can be compared to 
(Zhou et al., 2006). Additionally, we found that temporin-GH, which was isolated from the 
skin secretion of Hylarana guentheri by MS/MS sequencing in the literature, displays the 100% 
identity to the mature peptide domain of our translated open reading frame. Therefore, it is the 
first time to clone the transcript cDNA of the temporin-GH precursor in the skin secretion. In 
the alignment of the biosynthetic precursors from Hylarana guentheri, we expectedly observed 
the highly-conserved signal peptide domain among the candidates, even though two of them 
are members of the brevinin family. The phenomenon can often be found in the study of the 
skin defence peptides from same species or those of the same amphibian family (Pukala et al., 
2006). That the conserved gene encoding a variety of defence peptides in amphibian could be 
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the results of evolution that they are from the same ancestor. The phylogenetic trees of the 
different skin defence peptides demonstrate the processes of different species to produce 
bioactive peptides to adapt their living environment. As previous identification of temporin-
GH, we confirmed the presence of the common characteristics of C-terminal amidation. 
Obviously, that the -GK- is a motif indicating an amidation at the end of the mature peptide is 
also demonstrated among the natural bioactive peptides, such as phylloseptin and dermaseptin 
(Gao et al., 2016). Such widely occurring post-translational modification is considered to 
prevent from C-terminal related degradation as well as introducing positive charges to the 
peptide chain (Audagnotto and Dal Peraro, 2017).    
Since the determination of mature peptide sequence, synthetic replicates by solid phase peptide 
synthesis were subjected to antimicrobial and haemolytic assays.  Unexpectedly, QUB-1439 
only exhibits inhibitory effect against the growth of S. aureus, but no significant effect on the 
growth of E. coli and C. albicans up to the highest concentration. In our pervious study, we 
found that temporin-PE shows much more potent effect against the same microorganisms 
(Sang et al., 2017). The MICs of temporin-PE against S. aureus, E. coli and C. albicans are 2, 
16, and 4 respectively. As we are known, the net charge has been considered as an important 
role to manipulate the antimicrobial activity. The AMPs can attach to the bacteria cell surface 
through electrostatic interactions between the positive-charged side chains and the negatively-
charged lipid headgroups, and then AMPs could form transmembrane pore to alter the 
membrane permeability. Accordingly, temporin peptides can recognise the bacteria through 
the presence of Arg and Lys in the peptide chain and initiate the electrostatic attraction to the 
cell surface. However, we noticed that QUB-1439 only has a His in the peptide sequence, while 
temporin-PE possesses a Lys, which is more positive than QUB-1439. The potency of 
antimicrobial activity might be significantly altered by the presence of positively-charged 
amino acid residues, which explains the deficiency on antimicrobial effect of QUB-1439.  
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In the meantime, the hydrophobicity of peptide is also important on its antimicrobial activity. 
Studies illustrate that peptides contain more hydrophobic amino acids lead to higher 
antimicrobial activity. However, keeping increasing the hydrophobicity of antimicrobial 
peptides could result in the unspecific effect to permeate both bacterial and mammalian cell 
membrane, which could induce severe cytotoxicity and haemolysis(Raja et al., 2017). QUB-
1439 contains a relatively high degree of hydrophobicity, while it exhibits a low degree of 
haemolysis on horse red blood cells. Comparing to temporin-PE, QUB-1439 is even a slightly 
more hydrophobic, which is quite odd to the theory above. Sang et al. reported that the 
influence of hydrophobicity of temporin on the antimicrobial and haemolytic activities is 
related to the distribution of amino acids on the helical structural surface, generating the 
changes of the hydrophobic moment. Although QUB-1439 was predicted to form the α-helical 
structure, as same as temporin-PE. But, as the presence of a Lys at position 7 of temporin-PE, 
it shows a higher degree of the hydrophobic moment (0.570) than QUB-1439 (0.502), which 
makes temporin-PE more potent against bacteria, especially, gram-negative bacteria. Therefore, 
we assume that both positive charge and the hydrophobic moment could enhance the 
antimicrobial activity, but they contribute to different processes of the killing mechanism. 
Positive charge may enhance the electrostatic interaction between temporins and bacteria cell 
membrane, whilst hydrophobic moment could allow the peptide to form the transmembrane 
pore to permeabilise the cell membrane after the initial attachment of temporins.  
In the previous study, temporins were reported to inhibit the growth of Gram-positive bacteria 
mainly, but some of them show more potent activity with broad antimicrobial spectrum against 
both gram-positive and negative bacteria. For instance, temporin L shows potent effect against 
Gram-positive bacteria, Gram-negative bacteria, and fungi (Rinaldi et al., 2002). As a good 
template, the study of AMP design using temporin L was carried out. It was subjected to 
structural modification by introducing Trp residue in the sequence, which was used to increase 
  63 
the hydrophobicity of antimicrobial peptides because this substitution introduced large 
hydrophobic side chain to interact with the interfacial region of cell membrane, thus anchoring 
the peptide to the bilayer surface (Merlino et al., 2017). Therefore, the antimicrobial effect of 
QUB-1439 is much weaker than and temporin L because temporin L not only contains 3 more 
positive charges but also possesses optimised hydrophobicity and hydrophobicity that makes 
it easier to attach to the bacteria surface and permeabilise the cell membrane. 
Additionally, a lot of studies showed that some AMPs also exhibit anticancer activity through 
the mechanism of membrane disruption. To achieve this function, those AMPs usually have 
essential positive charges and well-characterised secondary structures. AMPs have activity 
against cancer cells because the chemical composition of a cancer cell is different from normal 
mammalian cell. Phosphatidylethanolamine (PE), phosphatidylcholine (PC) or sphingomyelin 
are the main component exist in the normal mammalian cells. These zwitterionic phospholipids 
make the normal cell have a neutral net charge, and they have less affinity to cationic AMPs. 
In reverse, cancer cells contain a lot of anionic molecules, like PS and glycosylated mucins, 
which makes them possess net negative charge (Gaspar et al., 2013). But in this study, QUB-
1439 do not produce remarkable anticancer activity on the selected cancer cell lines, though 
some temporin peptides have been detected to possess anticancer activity. Lack of cationic and 
rational distribution of amino acid residues among the helical structure is the main issue on the 
anticancer property of QUB-1439, which loses the ability to interact with the membrane of 
cancer cells (Gaspar et al., 2013, Schweizer, 2009).  
The length of temporin is also reported to influence the antimicrobial activity. The longer 
peptide chain, like temporin-ALa from the Chinese torrent frog Amolops loloensis containing 
16 residues, could be helpful on inhibiting the growth of both Gram-positive and Gram-
negative bacteria (Lu et al., 2006). Whilst, the contribution of extension of temporin peptides 
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on the improvement of biological activity may be related to the changes of net charge, 
hydrophobicity and hydrophobic moment. 
 
In summary, it is the first time to clone the cDNA encoding precursor of QUB-1439 (temporin-
GU) from the skin secretion of Hylarana guentheri. QUB-1439 only processes antimicrobial 
activity against the Gram-positive bacterium, while it has no toxicity and haemolysis, which 
means QUB-1439 could be used as a template for drug design due to the low degree of toxicity.  
By changing the structure of QUB-1439, such as containing more basic amino acid residue and 
improving the proportion of hydrophobicity, it would improve the antimicrobial activity and 
maybe anticancer activity, which makes the peptide the attractive candidate for a novel anti-
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